» Articles » PMID: 32045873

The Epigenetic Face of Lupus: Focus on Antigen-presenting Cells

Overview
Date 2020 Feb 12
PMID 32045873
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, epigenetic mechanisms became widely known due to their ability to regulate and maintain physiological processes such as cell growth, development, differentiation and genomic stability. When dysregulated, epigenetic mechanisms, may introduce gene expression changes and disturbance in immune homeostasis leading to autoimmune diseases. Systemic lupus erythematosus (SLE), the most extensively studied autoimmune disorder, has already been correlated with epigenetic modifications, especially in T cells. Since these cell rely on antigen presentation, it may be assumed that erroneous activity of antigen-presenting cells (APCs), culminates in T cell abnormalities. In this review we summarize and discuss the epigenetic modifications in SLE affected APCs, with the focus on dendritic cells (DCs), B cells and monocytes. Unravelling this aspect of SLE pathogenesis, might result in identification of new disease biomarkers and putative therapeutic approaches.

Citing Articles

RNA N4-acetylcytidine modification and its role in health and diseases.

Wang Q, Yuan Y, Zhou Q, Jia Y, Liu J, Xiao G MedComm (2020). 2025; 6(1):e70015.

PMID: 39764566 PMC: 11702397. DOI: 10.1002/mco2.70015.


Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients.

Sun S, Zhang X, Guo Q, Tang X, Shen W, Liang J BMC Rheumatol. 2024; 8(1):68.

PMID: 39695907 PMC: 11654433. DOI: 10.1186/s41927-024-00439-x.


Molecular profiling and therapeutic tailoring to address disease heterogeneity in systemic lupus erythematosus.

Karmakar A, Kumar U, Prabhu S, Ravindran V, Nagaraju S, Suryakanth V Clin Exp Med. 2024; 24(1):223.

PMID: 39294397 PMC: 11410857. DOI: 10.1007/s10238-024-01484-z.


Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease.

Nasa Y, Satake A, Tsuji R, Saito R, Tsubokura Y, Yoshimura H Front Immunol. 2024; 15:1326066.

PMID: 38665907 PMC: 11043470. DOI: 10.3389/fimmu.2024.1326066.


Mechanisms of NAT10 as ac4C writer in diseases.

Xie L, Zhong X, Cao W, Liu J, Zu X, Chen L Mol Ther Nucleic Acids. 2023; 32:359-368.

PMID: 37128278 PMC: 10148080. DOI: 10.1016/j.omtn.2023.03.023.